Vyne Therapeutics

YARW · NASDAQ

$20.21+$0.23 (+1.15%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $19.98

About YARW

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 10 full-time employees. The company went IPO on 2018-01-25. The company is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.

Employees: 10
Headquarters: Bridgewater, New Jersey
Listed: Jan 25, 2018
Sector: Health Care
Industry: Pharmaceuticals
Website: vynetherapeutics.com

Leadership

Vyne Therapeutics executives
Name	Title	Since	Age
David Domzalski	—	2020	58
Tyler Zeronda	—	—	39
Iain Stuart	—	—	51
Mutya Harsch	—	—	50
Patrick Lepore	—	—	69
Sharon Barbari	—	—	70
Steven Basta	—	2015	59
Elisabeth Sandoval Little	—	—	63

Similar companies

Companies in the same industry as Vyne Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.